| Literature DB >> 27238872 |
Renata Paleari1, Donatella Caruso2, Patricia Kaiser3, Cristian Gabriel Arsene4, Christine Schaeffer-Reiss5, Alain Van Dorsselaer5, Emmanuel Bissé6, Maria Ospina7, Víctor R De Jesús7, Barbara Wild8, Andrea Mosca9.
Abstract
The importance of hemoglobin A2 (HbA2) as an indicator of the presence of β-thalassemia was established many years ago. However, clinical application of recommended HbA2 cut off values is often hampered due to poor equivalence of HbA2 results among methods and laboratories. Thus, the IFCC standardization program for HbA2 was initiated in 2004 with the goal of achieving a complete reference system for this measurand. HbA2 standardization efforts are still in progress, including the development of a higher-order HbA2 reference measurement procedure and the preparation of a certified reference material in collaboration with the IRMM. Here, we review the past, present and future of HbA2 standardization and describe the current status of HbA2 testing.Entities:
Keywords: Analytical goals; Beta-thalassemia; Quality control; Reference materials; Reference measurement procedure; Standardization
Mesh:
Substances:
Year: 2016 PMID: 27238872 DOI: 10.1016/j.cca.2016.05.023
Source DB: PubMed Journal: Clin Chim Acta ISSN: 0009-8981 Impact factor: 3.786